NASDAQ:AKRO
Akero Therapeutics, Inc.
- Stock
locale
United Statesmarket
STOCKSindustry
Biotechnologywebsite
www.akerotx.comipo date
Jun 20, 2019
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohy...Show More
Earnings
Earnings Release in 13 daysEarnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus